ClinicalTrials.gg
Enrolling by invitationNCT04976322Updated Nov 13, 2026

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

A Phase 3 interventional study of Dapirolizumab pegol in Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL. Enrolling by invitation at 123 sites in 24 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026First site in Japan5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Planned enrollment
4th of 21
760 · median 54
Started
2021
the only one that year
Phase 3
9 of 21
2 open now
Registered
18th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 4th largest by planned enrollment, is the only one that started in 2021, is one of 9 in phase 3, and was the 18th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic lupus erythematosus
  • Dapirolizumab pegol
  • SLE
  • DZP
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment
  • The participant completed one of the parent studies within 4 weeks prior to entry to this study

Exclusion criteria

Exclusion Criteria:

- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing at the start of the study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
760 participants (estimated)

Study arms

  • Experimental
    Dapirolizumab pegol

    Subjects will receive dapriolizumab pegol throughout the Treatment Period.

    Drug: Dapirolizumab pegol

Interventions

  • Subjects will receive dapirolizumab pegol at prespecified time-points.

    Also known as: DZP, CDP7657

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) during the study

    Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

  2. Incidence of serious treatment-emergent adverse events during the study

    A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalisation or prolongation of existing hospitalisation * Results in persistent disability/incapacity * Is a congenital anomaly or birth defect * Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

  3. Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation

    Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Secondary outcomes

  1. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24

    BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

    Time frame: Week 24

  2. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48

    BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

    Time frame: Week 48

  3. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104

    BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

    Time frame: Week 104

  4. Achievement of LLDAS at Week 48

    Low lupus disease activity state (LLDAS) is defined as: * No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit * PGA ≤33 mm * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol

    Time frame: Week 48

  5. Achievement of LLDAS at Week 104

    Low lupus disease activity state (LLDAS) is defined as: * No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit * PGA ≤33 mm * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol

    Time frame: Week 104

  6. Achievement of BICLA response at Week 48 (using the parent study baseline as the reference point)

    A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled: 1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and 2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and 3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale

    Time frame: Week 48

  7. Achievement of BICLA response at Week 104 (using the parent study baseline as the reference point)

    A study participant is considered to be a BICLA responder if all of the following is fulfilled: 1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and 2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and 3. No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale

    Time frame: Week 104

  8. Achievement of SRI-4 response at Week 48 (using the parent study baseline as the reference point)

    The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met): * Reduction in SLEDAI-2K score of ≥4 * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline * No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.

    Time frame: Week 48

  9. Achievement of SRI-4 response at Week 104 (using the parent study baseline as the reference point)

    The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met): * Reduction in SLEDAI-2K score of ≥4 * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline * No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.

    Time frame: Week 104

  10. Change from parent study Baseline in FATIGUE-PRO Total score at Week 48

    The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.

    Time frame: From Baseline to Week 48

  11. Change from parent study Baseline in FATIGUE-PRO Total score at Week 104

    The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.

    Time frame: From Baseline to Week 104

  12. Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 48

    The achievement of a reduction in glucocorticoid dose from \>7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 48

    Time frame: From Baseline to Week 48

  13. Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 104

    The achievement of a reduction in glucocorticoid dose from \>7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 104

    Time frame: From Baseline to Week 104

07

Study locations

123 sites
  • Sl0046 50140
    Birmingham, Alabama 35294, United States
  • Sl0046 50058
    Avondale, Arizona 85392, United States
  • Sl0046 50662
    Glendale, Arizona 85306, United States
  • Sl0046 50052
    Phoenix, Arizona 85032, United States
  • Sl0046 50328
    Tucson, Arizona 85704, United States
  • Sl0046 50383
    Beverly Hills, California 90210, United States
  • Sl0046 50275
    La Palma, California 90623-1730, United States
  • Sl0046 50316
    San Leandro, California 94578, United States
  • Sl0046 50339
    Denver, Colorado 80230, United States
  • Sl0046 50239
    Brandon, Florida 33511, United States
  • Sl0046 50362
    Gainesville, Florida 32610, United States
  • Sl0046 50681
    Miami, Florida 33172, United States
  • Sl0046 50059
    Ormond Beach, Florida 32174, United States
  • Sl0046 50324
    Plantation, Florida 33324, United States
  • Sl0046 50329
    Tampa, Florida 33606, United States
  • Sl0046 50698
    Tampa, Florida 33618, United States
  • Sl0046 50368
    Atlanta, Georgia 30303, United States
  • Sl0046 50240
    Idaho Falls, Idaho 83404, United States
  • Sl0046 50699
    Chicago, Illinois 60616, United States
  • Sl0046 50474
    Hopkinsville, Kentucky 42240-1746, United States
  • Sl0046 50285
    Lake Charles, Louisiana 70605, United States
  • Sl0046 50660
    New Orleans, Louisiana 70112, United States
  • Sl0046 50015
    Hagerstown, Maryland 21740, United States
  • Sl0046 50219
    Detroit, Michigan 48201, United States
  • Sl0046 50273
    Las Vegas, Nevada 89128, United States
  • Sl0046 50366
    Canton, New York 13617, United States
  • Sl0046 50264
    Manhasset, New York 11030, United States
  • Sl0046 50334
    New York, New York 10032, United States
  • Sl0046 50238
    Charlotte, North Carolina 28211, United States
  • Sl0046 50147
    Hershey, Pennsylvania 17033, United States
  • Sl0046 50001
    Jackson, Tennessee 38305, United States
  • Sl0046 50738
    Bellaire, Texas 77401, United States
  • Sl0046 50418
    Colleyville, Texas 76034, United States
  • Sl0046 50050
    Beckley, West Virginia 25801, United States
  • Sl0046 60002
    Buenos Aires, Argentina
  • Sl0046 60029
    Mendoza, Argentina
  • Sl0046 60003
    Quilmes, Argentina
  • Sl0046 60022
    Quilmes, Argentina
  • Sl0046 60011
    San Juan, Argentina
  • Sl0046 60014
    San Miguel de Tucumán, Argentina
  • Sl0046 40123
    Brussels, Belgium
  • Sl0046 40189
    Plovdiv, Bulgaria
  • Sl0046 40380
    Sofia, Bulgaria
  • Sl0046 50374
    Calgary, Canada
  • Sl0046 50337
    Edmonton AB, Canada
  • Sl0046 50259
    Rimouski, Canada
  • Sl0046 50045
    Toronto, Canada
  • Sl0046 60015
    Santiago, Chile
  • Sl0046 60018
    Santiago, Chile
  • Sl0046 20128
    Beijing, China
  • Sl0046 20291
    Changchun, China
  • Sl0046 20019
    Guangzhou, China
  • Sl0046 20290
    Guilin, China
  • Sl0046 20020
    Shanghai, China
  • Sl0046 20346
    Shantou, China
  • Sl0046 20204
    Suzhou, China
  • Sl0046 20136
    Tianjin, China
  • Sl0046 20025
    Wenzhou, China
  • Sl0046 20180
    Wuhan, China
  • Sl0046 20273
    Yangzhou, China
  • Sl0046 20132
    Zhengzhou, China
  • Sl0046 60013
    Barranquilla, Colombia
  • Sl0046 60019
    Barranquilla, Colombia
  • Sl0046 60006
    Bogotá, Colombia
  • Sl0046 60027
    Bogotá, Colombia
  • Sl0046 60016
    Bucaramanga, Colombia
  • Sl0046 60007
    Chía, Colombia
  • Sl0046 60031
    Montería, Colombia
  • Sl0046 40066
    Prague, Czechia
  • Sl0046 40386
    Cologne, Germany
  • Sl0046 40072
    Freiburg im Breisgau, Germany
  • Sl0046 40027
    Herne, Germany
  • Sl0046 40078
    Leipzig, Germany
  • Sl0046 40402
    Tübingen, Germany
  • Sl0046 40715
    Vogelsang-gommern, Germany
  • Sl0046 40378
    Athens, Greece
  • Sl0046 40501
    Athens, Greece
  • Sl0046 40377
    Crete, Greece
  • Sl0046 40507
    Larissa, Greece
  • Sl0046 40412
    Budapest, Hungary
  • Sl0046 40411
    Debrecen, Hungary
  • Sl0046 40031
    Szeged, Hungary
  • Sl0046 40499
    Székesfehérvár, Hungary
  • Sl0046 40084
    Catania, Italy
  • Sl0046 40448
    Milan, Italy
  • Sl0046 20287
    Nagoya, Japan
  • Sl0046 50317
    Chihuahua City, Mexico
  • Sl0046 50250
    Cuernavaca, Mexico
  • Sl0046 50249
    Guadalajara, Mexico
  • Sl0046 50271
    León, Mexico
  • Sl0046 50252
    Mérida, Mexico
  • Sl0046 50251
    Monterrey, Mexico
  • Sl0046 60009
    Lima, Peru
  • Sl0046 60023
    Lima, Peru
  • Sl0046 20182
    Davao City, Philippines
  • Sl0046 20181
    Makati, Philippines
  • Sl0046 40482
    Bialystok, Poland
  • Sl0046 40119
    Bydgoszcz, Poland
  • Sl0046 40398
    Katowice, Poland
  • Sl0046 40502
    Krakow, Poland

Showing the first 100 of 123 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Aug 2030, 108 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 108 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 26, 2021
StartActual
Jul 27, 2021
Primary completionEst.
Aug 7, 2030
CompletionEst.
Aug 7, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed — first site in Japan
Show 5 added (2 Japan, 2 Serbia, 1 China)
  • Sl0046 20346 · Shantou, China
  • Sl0046 20287 · Nagoya, Japan
  • Sl0046 20171 · Sendai, Japan
  • Sl0046 40392 · Novi Sad, Serbia
  • Sl0046 40730 · Belgrade, Serbia
Show 1 removed
  • Sl0046 20171 · Sendai, Japan
across 2 updates, Oct 2, 2026 – Oct 15, 2026
Secondary outcomes
4 edited, 7 added, 1 removed, 2 description edited
What changed in the outcomes
  • EditedAchievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 5248Time frame: Week 52 → Week 48
  • EditedAchievement of LLDAS at ≥50% of all visitsWeek 48Time frame: From Baseline (Day 1) until End of Treatment (Week 104) → Week 48
  • EditedAchievement of BICLA responseLLDAS at Week 24104Time frame: Week 24 → Week 104
  • EditedAchievement of BICLA response at Week 104 (using the parent study baseline as the reference point)Time frame: Week 104
  • AddedAchievement of BICLA response at Week 48 (using the parent study baseline as the reference point)Time frame: Week 48
  • AddedAchievement of SRI-4 response at Week 48 (using the parent study baseline as the reference point)Time frame: Week 48
  • AddedAchievement of SRI-4 response at Week 104 (using the parent study baseline as the reference point)Time frame: Week 104
  • AddedChange from parent study Baseline in FATIGUE-PRO Total score at Week 48Time frame: From Baseline to Week 48
  • AddedChange from parent study Baseline in FATIGUE-PRO Total score at Week 104Time frame: From Baseline to Week 104
  • AddedPercentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 48Time frame: From Baseline to Week 48
  • AddedPercentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 104Time frame: From Baseline to Week 104
  • RemovedAchievement of BICLA response at Week 52Time frame: Week 52
  • DescriptionAchievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104: how it is measured was reworded
  • DescriptionAchievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24: how it is measured was reworded
Nov 13, 2026
Show all 3 updates
  1. Nov 13, 2026
    Secondary outcomes 4 edited, 7 added, 1 removed, 2 description edited
    What changed in the outcomes
    • EditedAchievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 5248Time frame: Week 52 → Week 48
    • EditedAchievement of LLDAS at ≥50% of all visitsWeek 48Time frame: From Baseline (Day 1) until End of Treatment (Week 104) → Week 48
    • EditedAchievement of BICLA responseLLDAS at Week 24104Time frame: Week 24 → Week 104
    • EditedAchievement of BICLA response at Week 104 (using the parent study baseline as the reference point)Time frame: Week 104
    • AddedAchievement of BICLA response at Week 48 (using the parent study baseline as the reference point)Time frame: Week 48
    • AddedAchievement of SRI-4 response at Week 48 (using the parent study baseline as the reference point)Time frame: Week 48
    • AddedAchievement of SRI-4 response at Week 104 (using the parent study baseline as the reference point)Time frame: Week 104
    • AddedChange from parent study Baseline in FATIGUE-PRO Total score at Week 48Time frame: From Baseline to Week 48
    • AddedChange from parent study Baseline in FATIGUE-PRO Total score at Week 104Time frame: From Baseline to Week 104
    • AddedPercentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 48Time frame: From Baseline to Week 48
    • AddedPercentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 104Time frame: From Baseline to Week 104
    • RemovedAchievement of BICLA response at Week 52Time frame: Week 52
    • DescriptionAchievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104: how it is measured was reworded
    • DescriptionAchievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24: how it is measured was reworded
    + 2 other changes: verification date and site details
  2. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • Sl0046 40730 · Belgrade, Serbia
    Show 1 removed
    • Sl0046 20171 · Sendai, Japan
    + 1 other change: verification date
  3. Oct 2, 2026
    4 sites added — first site in Japan
    Show 4 added (2 Japan, 1 China, 1 Serbia)
    • Sl0046 20346 · Shantou, China
    • Sl0046 20287 · Nagoya, Japan
    • Sl0046 20171 · Sendai, Japan
    • Sl0046 40392 · Novi Sad, Serbia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04976322
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jul 26, 2021
Start date
Jul 27, 2021
Primary completion
Aug 7, 2030 (estimated)
Completion
Aug 7, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion